| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Director
2 companies
R Michael Carruthers is Chief Financial Officer at EWTX and has filed Form 4s across 2 companies. R Michael Carruthers's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.3M at current prices.
Historically, R Michael Carruthers's trades have earned a below-average insider score of 46/100 across 6 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -49.1%.
The biggest single holding is EWTX (~$3.2M) as Chief Financial Officer. The EWTX filings lean toward selling, a net 221,327 shares.
R Michael Carruthers has 18 Form 4 filings on record from August 2021 to August 2026, across 2 companies: Director at OnKure Therapeutics (OKUR), 2024–2026; Chief Financial Officer at Edgewise Therapeutics (EWTX), 2021–2025.
The 35 reported transactions were 14 option or other derivative awards, 10 option exercises, 9 open-market sales and 2 stock awards.
Counted by filing, the open-market trades come to no purchases and 6 sales worth about $5.1M.
The largest open-market sale was 125,092 shares of EWTX at an average $28.57 on September 20, 2024, about $3.6M. Twelve months later EWTX was down 50%.
1 of the 6 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 5 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,428 | $13.39 | $19,124.35 | -1.6% | +36.5% | +225.3% | |
| May 2, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,314 | $16.45 | $21,620.82 | -1.6% | -15.7% | +81.0% | |
| Sep 20, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 125,092 | $28.57 | $3,573,979.93 | -94.8% | +8.9% | -49.6% | |
| May 2, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,157 | $18.91 | $40,788.87 | -5.8% | -11.7% | -12.3% | |
| Jan 23, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 90,000 | $15.78 | $1,419,759.00 | -75.6% | -2.5% | +75.5% | |
| May 2, 2023 | EWTX Edgewise Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,336 | $8.90 | $11,896.95 | -7.7% | -16.7% | +117.3% |